SCHEMBL17554154

SCHEMBL17554154

CN1CCN(CCCNC(=O)c2ccccc2NC(=O)c2ccc3ccccc3c2)CC1

nearest known ligand 0.68

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 5/20 0.68
PPARG P37231 2/20 0.66
POLB P06746 1/20 0.60
SLC6A4 P31645 5/20 0.60
SLC6A2 P23975 3/20 0.60
DRD3 P35462 7/20 0.58
HTR1A P08908 1/20 0.57
ADRA2A P08913 1/20 0.57
DRD2 P14416 6/20 0.56
ADRA1A P35348 5/20 0.56
DRD4 P21917 1/20 0.55
KDM4E B2RXH2 1/20 0.54
HSD17B10 Q99714 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17554043 0.89 POLB (0.77) NR1H4PPARGPOLBKDM4EHSD17B10
SCHEMBL17554103 0.86 ALDH1A1 (0.72) NR1H4POLB
SCHEMBL30560594 0.86 ALDH1A1 (0.72) NR1H4POLB
SCHEMBL17554074 0.84 HTR1A (0.66) NR1H4SLC6A4SLC6A2DRD3HTR1A
SCHEMBL17554050 0.83 KDM4E (0.68) PPARGPOLBSLC6A4DRD3DRD2
SCHEMBL10724572 0.83 DRD3 (0.78) SLC6A4SLC6A2DRD3HTR1AADRA2A
SCHEMBL17554159 0.82 CYP1A2 (0.78) NR1H4PPARGPOLBHTR1A
SCHEMBL17554040 0.81 BCL3 (0.78) POLBKDM4EHSD17B10
SCHEMBL30560619 0.81 BCL3 (0.78) POLBKDM4EHSD17B10
SCHEMBL17554076 0.80 POLB (0.67) POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3628374-B1 BCL-3 INHIBITORS UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) 2023-08-30 EP disclosed
EP-3628374-B1 BCL-3 INHIBITORS UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) 2023-08-30 EP disclosed
EP-3628374-A2 BCL-3 INHIBITORS University College Cardiff Consultants Limited (GB) 2020-04-01 EP disclosed
EP-3628374-A2 BCL-3 INHIBITORS University College Cardiff Consultants Limited (GB) 2020-04-01 EP disclosed
US-20190248756-A1 BCL-3 INHIBITORS UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) 2019-08-15 US disclosed
US-20190248756-A1 BCL-3 INHIBITORS UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) 2019-08-15 US disclosed
US-10273218-B2 BCL-3 inhibitors UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2019-04-30 US disclosed
US-10273218-B2 BCL-3 inhibitors UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2019-04-30 US disclosed
US-20170267653-A1 BCL-3 INHIBITORS UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2017-09-21 US disclosed
US-20170267653-A1 BCL-3 INHIBITORS UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2017-09-21 US disclosed
EP-3174602-A2 BCL-3 INHIBITORS University College Cardiff Consultants Limited (GB) 2017-06-07 EP disclosed
WO-2016016728-A2 BCL-3 INHIBITORS UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2016-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190248756-A1 BCL-3 INHIBITORS BCL3, BCL2, BCL2L13 NR1H4 2479/4885PPARG 3081/4885POLB 1797/4885
US-10273218-B2 BCL-3 inhibitors BCL3, BCL2, BCL2L13 NR1H4 2842/4885PPARG 2993/4885POLB 1339/4885
US-20170267653-A1 BCL-3 INHIBITORS BCL3, BCL2, BCL2L13 NR1H4 2842/4885PPARG 2993/4885POLB 1339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.